Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
Optimi Health completed a GMP production run of its 5mg psilocybin finished drug product at its British Columbia facility. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression, with an updated bottling configuration for ease of use.
Key figures
- Drug strength
- 5mg
- Biomass hold limit
- 2,000 kilograms
- Vault capacity value
- C$100 million
- Psilocybin hold limit
- 20 kilograms
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.